Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuya Hosaka

Showing results (181-190 of 306) with videos related to

Pageof 31
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 11, 2013
Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinomaYuya Seko, Kenji Ikeda, Yusuke Kawamura, et al.
Internal Medicine (Tokyo, Japan)|June 4, 2010
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus loadYasuji Arase, Fumitaka Suzuki, Norio Akuta, et al.
Journal of Gastroenterology|October 1, 2021
Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogsDaiki Yamashige, Tetsuya Hosaka, Fumitaka Suzuki, et al.
Journal of Medical Virology|April 22, 2009
Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitusNorio Akuta, Fumitaka Suzuki, Miharu Hirakawa, et al.
Journal of Medical Virology|November 22, 2005
Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral loadNorio Akuta, Fumitaka Suzuki, Hitomi Sezaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 29, 2014
Therapeutic effects of short- and intermediate-term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosisShintaro Akiyama, Kenji Ikeda, Hitomi Sezaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 2, 2005
Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3cm or less in diameterKenji Ikeda, Masahiro Kobayashi, Satoshi Saitoh, et al.
Journal of Medical Virology|December 2, 2009
Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1bMariko Kobayashi, Norio Akuta, Fumitaka Suzuki, et al.
Journal of Clinical Microbiology|June 21, 2013
Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1Norio Akuta, Fumitaka Suzuki, Taito Fukushima, et al.
Gut and Liver|September 28, 2013
What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot StudyYusuke Kawamura, Kenji Ikeda, Taito Fukushima, et al.
Pageof 31

Showing results (181-190 of 306) with videos related to

Sort By:
Pageof 31
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 11, 2013
Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinomaYuya Seko, Kenji Ikeda, Yusuke Kawamura, et al.
Internal Medicine (Tokyo, Japan)|June 4, 2010
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus loadYasuji Arase, Fumitaka Suzuki, Norio Akuta, et al.
Journal of Gastroenterology|October 1, 2021
Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogsDaiki Yamashige, Tetsuya Hosaka, Fumitaka Suzuki, et al.
Journal of Medical Virology|April 22, 2009
Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitusNorio Akuta, Fumitaka Suzuki, Miharu Hirakawa, et al.
Journal of Medical Virology|November 22, 2005
Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral loadNorio Akuta, Fumitaka Suzuki, Hitomi Sezaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 29, 2014
Therapeutic effects of short- and intermediate-term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosisShintaro Akiyama, Kenji Ikeda, Hitomi Sezaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 2, 2005
Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3cm or less in diameterKenji Ikeda, Masahiro Kobayashi, Satoshi Saitoh, et al.
Journal of Medical Virology|December 2, 2009
Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1bMariko Kobayashi, Norio Akuta, Fumitaka Suzuki, et al.
Journal of Clinical Microbiology|June 21, 2013
Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1Norio Akuta, Fumitaka Suzuki, Taito Fukushima, et al.
Gut and Liver|September 28, 2013
What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot StudyYusuke Kawamura, Kenji Ikeda, Taito Fukushima, et al.
Pageof 31